国产合成生物龙头冲击港交所

Core Viewpoint - Anhui Huaheng Biological Technology Co., Ltd. (Huaheng Bio) is planning to raise funds through its listing on the Hong Kong Stock Exchange to support global business expansion, synthetic biology enabling technology, new product and solution development, capacity upgrades, working capital, and general corporate purposes [2][3]. Group 1 - Huaheng Bio was established in 2005 and is a pioneer in synthetic biology technology, focusing on the research, large-scale production, and commercialization of bio-based products [5]. - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on April 22, 2021 [5]. - According to Frost & Sullivan, Huaheng Bio is one of the most comprehensive companies in the commercial application of bio-based products through synthetic biology technology [7]. Group 2 - Huaheng Bio is the first company globally to industrialize a series of amino acids, including L-Alanine and L-Valine, through anaerobic fermentation [7]. - By 2024, Huaheng Bio is projected to hold the largest market share for L-Alanine and L-Valine globally [7].